Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1196 results
May 2018
-
Media ReleaseSandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseasesEuropean Commission's (EC) approval based on comprehensive data package confirming that Zessly® matches safety, efficacy and quality of reference medicine Biosimilars such as Zessly enable…
-
Key ReleaseNovartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine preventionMigraine is a severe neurologic disease that profoundly impacts millions of patients in the United States Aimovig is the first and only FDA-approved treatment to block the calcitonin gene-…
-
Media ReleaseNovartis data at ASCO and EHA reinforce company's commitment to reimagining cancerResults from the Kisqali® MONALEESA clinical trial program, the largest industry- sponsored Phase III registration program researching a CDK4/6 inhibitor in HR+/HER2- advanced breast cancer, will…
-
Media ReleaseNovartis kündigt Veränderungen in der Geschäftsleitung anFelix R. Ehrat, Group General Counsel, tritt per 1. Juni 2018 zurück Shannon Thyme Klinger zum Group General Counsel ernannt Robert Weltevreden zum Leiter Novartis Business Services ernannt…
-
Media ReleaseAt the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive sustainable growthFull pipeline of late stage assets with blockbuster potential Positioned to deliver sales growth and margin expansion through 2022 Pipeline depth in key therapeutic areas and building new,…
-
Media ReleaseNovartis announces changes to the Executive CommitteeFelix R. Ehrat, Group General Counsel, will retire on June 1, 2018 Shannon Thyme Klinger appointed to Group General Counsel Robert Weltevreden appointed Head of Novartis Business Services…
-
Media ReleaseNovartis successfully completes acquisition of AveXis, Inc.The digital press release with multimedia content can be accessed here: Basel, May 15, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced that it has completed the acquisition of…
-
Media ReleaseNovartis ARROW trial to assess mechanistic superiority of direct IL-17A inhibition (Cosentyx®) over IL-23 inhibition (Tremfya®*)ARROW study to assess the mechanistic superiority of direct IL-17A inhibition (Cosentyx) over IL-23 inhibition (Tremfya®*) in clearing of Stelara®*-resistant psoriatic plaques[1] This is the…
-
Media ReleaseNovartis completes tender offer for all outstanding shares of AveXis, Inc.Basel, May 15, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced the successful completion of the previously announced tender offer by its indirect wholly-owned subsidiary, Novartis AM…
-
Media ReleaseNovartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosisNew approval for Gilenya (fingolimod) addresses strong unmet need for younger patients, who often experience more frequent relapses than adults with multiple sclerosis (MS)[1] In a…
-
Media ReleaseAlcon Cares Project 100 Commits to Reducing Cataract Blindness GloballyAlcon Cares to donate 100 reprocessed Infiniti® units to clinics helping underserved patients in Asia, Central and South America, and Africa over the next three years Program to increase…
-
Media ReleaseAveXis Reports First Quarter 2018 Financial and Operating Results-- Significant progress across operating functions including licensing, clinical trials and regulatory interactions -- -- AVXS-101 pre-BLA meeting with FDA is scheduled to be…
Pagination
- ‹ Previous page
- 1
- …
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- …
- 100
- › Next page